Tirzepatide is a once-weekly injectable medication used primarily to manage blood sugar levels in people with type 2 diabetes. It is a dual-action drug that mimics the effects of two incretin hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By activating both receptors, tirzepatide helps stimulate insulin release, reduce appetite, slow digestion, and lower blood sugar after meals.

Beyond its impact on blood sugar control, tirzepatide has shown promising results in promoting weight loss, making it an attractive option for individuals struggling with obesity and metabolic issues. Studies indicate that tirzepatide may lead to significant weight reduction by curbing hunger and enhancing energy expenditure. This dual-receptor action offers an advantage over traditional GLP-1 receptor agonists, potentially providing more substantial benefits for both blood sugar control and weight management.